Results for tag: "Vitiligo Drug"

The Vitiligo Drug market is a subset of the Dermatological Drugs market, which includes drugs used to treat skin conditions. Vitiligo is a skin condition characterized by the loss of skin color in patches, and is caused by the destruction of melanocytes, the cells responsible for skin pigmentation. Vitiligo drugs are used to treat the condition by restoring the skin's pigmentation. The Vitiligo Drug market is composed of a variety of drugs, including topical corticosteroids, topical calcineurin inhibitors, phototherapy, and systemic medications. Topical corticosteroids are used to reduce inflammation and stimulate melanocyte production, while topical calcineurin inhibitors are used to reduce inflammation and prevent the destruction of melanocytes. Phototherapy is used to stimulate melanocyte production, while systemic medications are used to reduce inflammation and stimulate melanocyte production. The Vitiligo Drug market is highly competitive, with a number of companies offering products to treat the condition. Some of the companies in the market include Novartis, Sun Pharmaceuticals, Glenmark Pharmaceuticals, and Mylan Pharmaceuticals. Show Less Read more